Study guide: Diffuse Interstitial Lung Disease Fundamentals

📋 Course Outline

1. Definition and pulmonary interstitium
2. Pathogenesis of interstitial infiltrates
3. Classification of diffuse interstitial lung disease
4. Diagnostic workup for PID
5. Major etiologies of chronic PID
6. Clinical course and complications
7. Treatment principles
8. Idiopathic pulmonary fibrosis and sarcoidosis

📖 1. Definition and pulmonary interstitium

🔑 Key Concepts & Definitions

• Diffuse infiltrative interstitial pneumopathies: Diffuse infiltrative interstitial pneumopathies are a heterogeneous group defined by diffuse interstitial infiltration visible on imaging.
• Pulmonary interstitium: Pulmonary interstitium is the supporting connective tissue of bronchovascular axes, inter- and intralobular septa, and the tissue under pleura with interalveolar septa.
• Interstitial infiltration pattern: Interstitial infiltration can be cellular or fibrous, and fibrosis is described as irreversible in these diseases.
• Diffuse interstitial opacities: Diffuse interstitial opacities are the shared radiologic presentation across these pneumopathies.

📝 Essential Points

• Interstitial involvement can include the interstitium only, or alveolar space involvement that may dominate the presentation in some entities.
• Histopathology includes interstitial cellular or fibrous infiltrate, with fibrosis stated as irreversible.
• Pulmonary interstitium infiltration leads to impaired gas diffusion and impaired elastic system function.

💡 Memory Hook

Interstitium = “support beams” for airways and septa; when infiltrated, gas transfer and elasticity fail.

📖 2. Pathogenesis of interstitial infiltrates

🔑 Key Concepts & Definitions

• Variable intensity and location: Interstitial infiltration varies in intensity and in where it occurs within the pulmonary interstitium.
• Mesenchymal cellular reaction: A reaction after initial aggression involves accumulation of mesenchymal cells to drive tissue repair.
• Repair process overshoot: When the initial process persists, tissue repair goes beyond its purpose and leads to fibrosis.

📝 Essential Points

• Cellular elements involved may be inflammatory, hyperplastic, or neoplastic, while non-cellular elements may include edema and collagen changes.
• Non-cellular contributors can include organic or mineral components that infiltrate the interstitium.
• The sequence described is initial aggression → inflammatory reaction with mesenchymal accumulation → tissue repair → fibrosis if the trigger persists.

💡 Memory Hook

Aggression that won’t stop turns repair into fibrosis.

📖 3. Classification of diffuse interstitial lung disease

🔑 Key Concepts & Definitions

• Acute PID: Acute PID are defined as interstitial pneumopathies with rapid onset, lasting less than 3 weeks.
• Subacute or chronic PID: Subacute or chronic PID are a heterogeneous group managed with a different diagnostic approach than acute PID.
• 4 major etiologies of acute PID: Acute PID are described as dominated by four major etiologic categories in the course of the diagnostic strategy.

📝 Essential Points

• Acute PID are presented as less than 3 weeks and include infectious causes, hemodynamic causes, ARDS, and acute exacerbation of a subacute/chronic PID.
• Subacute/chronic PID are split into PID of known cause and PID of unknown cause for epidemiologic and practical reasons.
• Specific named entities for subacute/chronic PID include sarcoidosis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, organizing pneumonia, and others listed in the course classification.

💡 Memory Hook

Time splits strategy: <3 weeks = acute; otherwise = known vs unknown cause.

📖 4. Diagnostic workup for PID

🔑 Key Concepts & Definitions

• Multidisciplinary approach: Diagnostic workup for PID uses a multidisciplinary team including pneumology, internal medicine, radiology, anatomo-pathology, and surgery.
• HRCT chest: High-resolution CT with 1 mm slice thickness is a key diagnostic exam that analyzes elementary imaging signs.
• BAL lymphocyte pattern: Bronchoalveolar lavage direction can be guided by the cellular profile found in the lavage.
• Restrictive ventilatory disorder: A restrictive ventilatory disorder in PID is characterized by reduced total lung capacity and preserved or increased ratios depending on the described criteria.

📝 Essential Points

• For acute PID (<3 weeks), the diagnostic approach uses a bundle of arguments including history, clinical signs, imaging, biology, pulmonary function tests, histology, and BAL.
• Subacute/chronic PID workup starts with an interview focusing on age/sex/ethnicity, smoking/drug use, medication history, prior radiotherapy, occupational and domestic exposures, family history, and signs of systemic disease.
• Clinical exam includes systemic features such as fever, weight loss, asthenia, connective-tissue signs, and auscultation findings like “velcro” dry crackles and digital clubbing.
• Radiography is used to confirm the diagnosis, assess lesion extent, and evaluate evolutionary rapidity with attention to retraction and reduced lung volumes.
• HRCT elementary lesions are described as reticular opacities, micronodules, ground-glass, and alveolar opacities.

💡 Memory Hook

Workup order: history/exam → imaging (CXR then HRCT) → PFT/BAL/histology with a multidisciplinary team.

📖 5. Major etiologies of chronic PID

🔑 Key Concepts & Definitions

• Connective-tissue related PID: Connective-tissue and vasculitis etiologies are listed among subacute/chronic diffuse PID causes.
• Granulomatous PID: Granulomatous PID include sarcoidosis and chronic granulomatous causes listed in the course.
• Known-cause PID by exposure: Known-cause PID includes hypersensitivity pneumonitis and pneumoconioses from repeated organic or mineral dust exposure.
• Drug-induced PID: Drug-induced PID are recognized as having multiple mechanisms and can appear as acute, subacute, or chronic patterns.

📝 Essential Points

• Connective-tissue diseases listed include Sjögren syndrome, rheumatoid arthritis, scleroderma, disseminated lupus erythematosus, polymyositis/dermatomyositis, and mixed connective tissue disease.
• Granulomatous PID examples include sarcoidosis with epitheloid and giant-cell granulomas without caseous necrosis and exclusion of other granulomatosis causes, and Langerhans cell histiocytosis with tobacco link described as “Tabac+++.”
• Hypersensitivity pneumonitis is linked to repeated exposure to organic antigens with an acute and/or chronic presentation, including occupational settings such as bird breeders and “farmer’s lung.”
• Pneumoconioses are grouped as fibrogenic (silicose, asbestosis) versus non-fibrogenic granulomatous (berylliosis), with exposure context and radio-clinical imaging used alongside HRCT/EFR and mineralogical study in BAL.
• Drug-induced PID requires diagnostic exclusion and includes examples such as amiodarone, bleomycin, cyclophosphamide, hydralazine, methotrexate, nitrofurantoin, procainamide, penicillamine, and gold salts.
• Other etiologies listed include lymphangioleiomyomatosis, eosinophilic lung diseases, primitive alveolar proteinosis, amyloidosis, lipid pneumonia, and metabolic storage disorders.

💡 Memory Hook

Chronic PID etiologies cluster into: connective tissue/vasculitis, granulomas, exposure (organic/mineral), drugs, then “other named diseases.”

📖 6. Clinical course and complications

🔑 Key Concepts & Definitions

• Outcome by etiology: Clinical evolution is presented as depending on the underlying etiology of the PID.
• Spontaneous resolution: Some PID are described as able to resolve spontaneously depending on the cause.

📝 Essential Points

• Evolution includes resolution in sarcoidosis and exacerbation of idiopathic pulmonary fibrosis with progression to chronic respiratory failure, pulmonary hypertension, infections, and bronchial cancer.
• Idiopathic pulmonary fibrosis is stated to be associated with a mortality outcome emphasized in the conclusion.

💡 Memory Hook

Cause drives outcome: sarcoidosis → possible resolution; idiopathic pulmonary fibrosis → worsening complications.

📖 7. Treatment principles

🔑 Key Concepts & Definitions

• Treat identifiable cause: When a cause is identified, treatment focuses on that cause as a core principle.
• Eviction of responsible agent: Avoiding the responsible exposure is a treatment principle when a specific agent is implicated.
• Smoking cessation: Smoking cessation is emphasized for PID related to tobacco exposure.
• Symptomatic oxygen therapy: Symptomatic treatment in chronic respiratory impairment can include oxygen therapy.

📝 Essential Points

• Treatment principles include managing an identified cause (e.g., infection), avoiding the responsible agent (e.g., hypersensitivity pneumonitis), and stopping tobacco for tobacco-related PID.
• If there is doubt about a cardiac component, diuretic testing is proposed as an approach in the treatment strategy.
• Oxygen therapy is used in chronic respiratory insufficiency when indicated.
• In acute hypoxemic interstitial pneumonia situations, management is described through intensive care and specific treatment such as therapy for pneumocystis.
• For idiopathic pulmonary fibrosis, antifibrotic therapy examples are pirfenidone and nintedanib, and transplantation is described as an option.

💡 Memory Hook

Principles = cause first, then remove exposure, then support (oxygen) and specific acute management.

📖 8. Idiopathic pulmonary fibrosis and sarcoidosis

🔑 Key Concepts & Definitions

• Idiopathic pulmonary fibrosis: Idiopathic pulmonary fibrosis is a named fibrosing PID entity treated with antifibrotic drugs and can require transplantation.
• Sarcoidosis monitoring and treatment tiers: Sarcoidosis management is described as surveillance in some asymptomatic cases and anti-inflammatory or immunosuppressive treatment in others based on risk and organ involvement.
• Lofgren syndrome: Lofgren syndrome is a sarcoidosis form described as treated with an anti-inflammatory approach.

📝 Essential Points

• Idiopathic pulmonary fibrosis is stated as having a median survival of 2.5 to 3.5 years and a 10-year survival around 10%.
• In idiopathic pulmonary fibrosis, corticosteroids and immunosuppressors are stated as having no place in the course.
• Sarcoidosis management includes surveillance for an asymptomatic patient without severe extrarespiratory involvement.
• For sarcoidosis with Lofgren syndrome, an anti-inflammatory approach is indicated.
• For sarcoidosis with asymptomatic but severe extrarespiratory involvement, corticosteroid therapy is described with or without immunosuppressive association.
• For symptomatic sarcoidosis, risk is evaluated (low/moderate/high) and treatment includes prednisone 20 mg/day with immunosuppressors depending on evolution and risk assessment.

💡 Memory Hook

IPF = “no steroid/immunosuppressor place,” Sarcoid = “Lofgren anti-inflammatory; risk-stratified steroids +/− immunosuppression.”

⚠️ Common Pitfalls & Confusions

1. Mixing acute and subacute/chronic PID: acute PID are <3 weeks and follow a different diagnostic strategy than subacute/chronic PID.
2. Confusing imaging roles: radiography is for confirmation/extent/rapidity, while HRCT (1 mm HR slices) is the key diagnostic exam.
3. Assuming fibrosis is always reversible: the course states that fibrosis in these interstitial infiltrates is irreversible.
4. Using restrictive PFT criteria incorrectly: the course specifies TVR with CPT <80% and a pattern with VEMS/CVL > 70%.
5. For idiopathic pulmonary fibrosis, incorrectly using corticosteroids/immunosuppressors: the course states no place for them.
6. For sarcoidosis, giving one-size-fits-all therapy: management is separated by symptoms and extrarespiratory severity/risk.

✅ Exam Checklist

1. Define PID in terms of diffuse interstitial infiltration and shared radiologic presentation.
2. Identify the pulmonary interstitium structures involved and state at least two consequences of interstitial infiltration.
3. Describe the pathogenesis sequence from initial aggression to fibrosis if persistence occurs.
4. Differentiate acute PID (<3 weeks) from subacute/chronic PID and list the four major etiologic categories for acute PID.
5. Classify subacute/chronic PID into known-cause versus unknown-cause categories.
6. List the key steps of the diagnostic workup approach for PID subacute/chronic (interview, clinical exam, imaging strategy, HRCT features).
7. State the HRCT elementary lesions and how localization, extent, and relation to anatomic structures orient diagnosis.
8. Use PFT criteria from the course to recognize restrictive ventilatory disorder and state the additional diffusion/oxygenation abnormalities.
9. Explain how BAL cellular profiles can orient etiology, including at least one mapping from lymphocytes/neutrophils/eosinophils to named causes.
10. Recall the major chronic PID etiologic groups and provide one example from each group listed (connective tissue/vasculitis, granulomatous, exposure, drugs, others).
11. State core treatment principles: treat cause, evict agent, stop smoking, and provide symptomatic oxygen when indicated.
12. For idiopathic pulmonary fibrosis and sarcoidosis, give at least one treatment option and one prognostic or dosing fact stated in the course.